Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 6,122 matching trials from the live ClinicalTrials.gov search.
Filters: "type 2 diabetes" Clear all
Completed Phase 2 Interventional

Clamp Study Comparing Inhalation of Technosphere®/Insulin in Smokers and Non-Smokers With Type 2 Diabetes

NCT00934414
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Technosphere Insulin Inhalation Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
20 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2009 · Synced Oct 15, 2026, 10:53 AM EDT
Completed No phase listed Observational

Delaying the Progression of Diabetic Nephropathy in Pima Indians

NCT00353600
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2011
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 15, 2026, 10:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Neurobehavioral Plasticity to Regular Sugar-Sweetened Beverage Intake: An fMRI Experiment

NCT03490734
View directory record Official record
Conditions
Obesity, Weight Gain
Interventions
Black Cherry and Orange Flavored Beverage with added sugar, Strawberry Kiwi &Lemonade Flavored Beverage with added sugar, Black Cherry and Orange Flavored Beverage no added sugar, Strawberry Kiwi & Lemonade Flavored Beverage no added sugar, Water
Dietary Supplement · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 28 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 15, 2026, 10:53 AM EDT
Completed Not applicable Interventional

Grains Reduce Adiposity and Improve Nutrition Study

NCT00924521
View directory record Official record
Conditions
Metabolic Syndrome, Insulin Resistance
Interventions
Whole grain diet, Refined grain
Dietary Supplement
Lead sponsor
Penn State University
Other
Eligibility
35 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 15, 2026, 10:53 AM EDT
Not listed Not applicable Interventional

iCan Diabetes Self-management and Prevention Program

NCT05571436
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, PreDiabetes
Interventions
iCan Diabetes Self-management and Prevention Support Group
Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 15, 2026, 10:53 AM EDT
Completed Not applicable Interventional Results available

Metabolic Study of Sleep Apnea in Men and Women

NCT00706511
View directory record Official record
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
CPAP
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 15, 2026, 10:53 AM EDT
Withdrawn No phase listed Observational

Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas

NCT05102071
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions
empagliflozin, metformin, sulfonylurea
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ridgefield, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 15, 2026, 10:53 AM EDT
Not listed Not applicable Interventional

Go Girls! Fitness Support Group Intervention Effectiveness Study

NCT02117063
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Abnormal Weight Gain, Excess Weight, Insulin Resistance, Premature Adrenarche, Type 2 Diabetes Mellitus
Interventions
Go Girls! Fitness Support Group
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 18 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 15, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus

NCT01177163
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, JNJ 28431754 300 mg/placebo, JNJ 28431754 100 mg/placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Chula Vista, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Oct 15, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional

A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin

NCT02053116
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PF-05175157, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 15, 2026, 10:53 AM EDT
Recruiting Phase 3 Interventional

A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease

NCT07843472
View directory record Official record
Conditions
Obesity or Overweight, Cardiovascular Disease
Interventions
Petrelintide, Placebo
Combination Product
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Anniston, Alabama • Los Angeles, California • Port Orange, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 15, 2026, 10:53 AM EDT
Terminated Phase 4 Interventional Results available

Treatment of GLP-1 for Diabetic Bariatric Patients

NCT04624672
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide (1 Mg Dose), Placebo
Drug
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 15, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Behavioral Economic Incentives to Improve Glycemic Control Among Adolescents and Young Adults

NCT02568501
View directory record Official record
Conditions
Diabetes, Type 1 Diabetes
Interventions
Daily feedback, Financial incentive
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
14 Years to 20 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 11, 2016 · Synced Oct 15, 2026, 10:53 AM EDT
Completed Not applicable Interventional Results available

Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use

NCT02137512
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Closed-Loop Control System, Sensor-Augmented Pump (SAP)
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years to 69 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Santa Barbara, California • Stanford, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Oct 15, 2026, 10:53 AM EDT
Completed Phase 3 Interventional

A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)

NCT06269107
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
IcoSema, Insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
43
States / cities
Birmingham, Alabama • Concord, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 15, 2026, 10:53 AM EDT
Completed Phase 2 Interventional

Examining the Effects of Diet on Health With an Online Program

NCT01967992
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Behavioral: Low Carbohydrate, Ketogenic Diet, American Diabetes Association Diet, Mindfulness and Positive Affect Skills
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 15, 2026, 10:53 AM EDT
Completed Phase 2 Interventional

Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes

NCT00110864
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PN2034, Insulin
Drug
Lead sponsor
Wellstat Therapeutics
Industry
Eligibility
21 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Waterbury, Connecticut • Hollywood, Florida • Longwood, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2007 · Synced Oct 15, 2026, 10:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intrapartum Glucose Management Among Women With Gestational Diabetes Mellitus

NCT02596932
View directory record Official record
Conditions
Gestational Diabetes Mellitus
Interventions
Standard Protocol for intrapartum glucose management, Experimental Protocol for intrapartum glucose management
Other
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 15, 2026, 10:53 AM EDT
Completed Not applicable Interventional Results available

Michigan Men's Diabetes Project

NCT04760444
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Peer Leader Diabetes Self-Management Support, Virtual Diabetes Self-Management Education
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
55 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 15, 2026, 10:53 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Using Virtual Reality to Improve Medical Training

NCT07542834
View directory record Official record
Conditions
Type 2 Diabetes (T2DM), Geriatric Syndromes, Disability Hearing, Disability Physical, Urinary Tract Infection(UTI), Delirium Confusional State
Interventions
Cinematic Virtual Reality Training, Traditional Didactic Lecture
Behavioral
Lead sponsor
Ohio University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 15, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Dose-ranging Study in Patients With Type 1 Diabetes Mellitus

NCT02459899
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Placebo, Sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
17
States / cities
Concord, California • Ventura, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 15, 2026, 10:53 AM EDT
Terminated Not applicable Interventional

A Surgical Approach to the Management of Type II Diabetes Mellitus in Patients With a BMI Between 25-35 kg/m2

NCT01197963
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sleeve Gastrectomy and Ileal transposition, dietary and medical management
Procedure · Dietary Supplement
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 15, 2026, 10:53 AM EDT
Completed Not applicable Interventional

The Impact of Low-fat and Full-fat Dairy Consumption on Glucose Homeostasis (DAIRY Study)

NCT02663544
View directory record Official record
Conditions
Insulin Resistance, Metabolic Syndrome, Obesity, Diabetes, NAFLD, Inflammation
Interventions
Limited dairy diet, Low-fat dairy diet, Full-fat dairy diet
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 15, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

NCT01555164
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo to match ranolazine, Metformin, Placebo to match metformin, Diet, Exercise
Drug · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
60
States / cities
Gulf Shores, Alabama • Little Rock, Alaska • Chandler, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Oct 15, 2026, 10:53 AM EDT